Hematologic cancer is any cancer that starts in the blood, bone marrow, or lymphatic system. Unlike solid tumors that form a mass in one organ, these cancers disrupt the production and function of blood cells, which means their effects are often felt throughout the body. The three main categories are leukemia, lymphoma, and myeloma, and together they account for roughly 192,000 new diagnoses in the United States each year.
How Blood Cell Production Goes Wrong
To understand hematologic cancer, it helps to know how blood cells are normally made. Your bone marrow contains stem cells that develop along two pathways. One pathway, called the myeloid line, produces red blood cells, platelets, and certain infection-fighting white blood cells like neutrophils. The other, called the lymphoid line, produces lymphocytes and natural killer cells, which are key players in your immune system.
Hematologic cancers occur when cells along either of these pathways begin growing uncontrollably. The specific type of cancer depends on which cell is affected, how mature it was when it became cancerous, and how quickly the abnormal cells multiply. Modern classification also factors in the genetic mutations driving the cancer, which increasingly guides treatment decisions.
Leukemia: Cancer in the Blood and Bone Marrow
Leukemia starts in the bone marrow and floods the bloodstream with abnormal white blood cells. It’s divided first by speed: acute leukemia progresses within weeks and causes rapid illness, while chronic leukemia may develop so slowly that people have no symptoms for years. It’s then divided by cell type: myeloid leukemia arises from the myeloid line, and lymphocytic leukemia arises from the lymphoid line. That gives four main forms: acute myeloid, acute lymphoblastic, chronic myeloid, and chronic lymphocytic.
The distinction between acute and chronic matters enormously. In acute leukemia, abnormal cells divide rapidly and never mature into functioning blood cells. You can go from feeling fine to seriously ill in a matter of weeks. Chronic leukemia cells retain some ability to function, behaving as partly mature cells. The disease worsens gradually, and some people live with it for years before needing treatment. An estimated 67,790 new leukemia cases will be diagnosed in 2026, with a five-year relative survival rate of 68.6%.
Lymphoma: Cancer of the Lymphatic System
Lymphoma develops in the lymphatic system, a network of vessels, nodes, and organs (including the spleen and tonsils) that helps filter waste and fight infections. It typically starts in lymphocytes, a type of white blood cell. The two broad categories are Hodgkin lymphoma and non-Hodgkin lymphoma, and the distinction comes down to a single microscopic detail: whether a specific abnormal cell called a Reed-Sternberg cell is present. If it is, the cancer is classified as Hodgkin lymphoma. If not, it’s non-Hodgkin.
Non-Hodgkin lymphoma is far more common, with about 79,320 new cases expected in 2026 compared to roughly 8,920 cases of Hodgkin lymphoma. Hodgkin lymphoma usually arises from B lymphocytes, while non-Hodgkin lymphoma can develop from B cells, T cells, or natural killer cells. This wider range of cell origins is one reason non-Hodgkin lymphoma includes more than 60 distinct subtypes, some aggressive and some so slow-growing they behave more like chronic conditions, relapsing over many years. Hodgkin lymphoma carries a five-year survival rate of 89.3%, while non-Hodgkin lymphoma sits at 74.3%.
Myeloma: Cancer of Plasma Cells
Multiple myeloma starts in plasma cells, a type of white blood cell that normally produces antibodies to fight infections. In myeloma, abnormal plasma cells accumulate in the bone marrow and produce a useless antibody protein called M protein. This protein doesn’t help fight infection but does build up in the blood, thickening it and potentially damaging the kidneys.
As myeloma cells multiply, they crowd out normal blood cell production. That means fewer red blood cells (causing anemia and fatigue), fewer healthy white blood cells (increasing infection risk), and fewer platelets (leading to easy bruising and bleeding). Myeloma cells also directly weaken bone, which is why bone pain, particularly in the spine or ribs, is one of the hallmark symptoms. About 36,000 new cases are expected in 2026, with a five-year survival rate of 63.7%. Encouragingly, myeloma death rates have been dropping by roughly 5% per year, the steepest decline among all hematologic cancers.
Common Symptoms Across Blood Cancers
Because hematologic cancers interfere with normal blood cell production, many symptoms overlap regardless of the specific type. The most common are persistent fatigue, shortness of breath, swollen lymph nodes, and frequent infections. These reflect the underlying problem: not enough healthy red blood cells to carry oxygen, and not enough functional white blood cells to fight off illness.
Other symptoms include unexplained weight loss, drenching night sweats, persistent fever, bone or joint pain, and unusual bruising or bleeding. Some people notice tiny red spots on their skin or purplish patches, which signal low platelet counts. An enlarged liver or spleen can cause a feeling of fullness or discomfort in the abdomen. Many of these symptoms are vague enough to be mistaken for less serious conditions, which is part of why blood cancers are sometimes caught late.
How Blood Cancers Are Diagnosed
Diagnosis usually begins with a complete blood count, a routine blood test that reveals whether blood cell levels are abnormally high or low. A blood chemistry test can also detect unusual proteins, like the M protein seen in myeloma, that suggest cancer.
If these initial tests raise suspicion, more specialized testing follows. A bone marrow biopsy involves extracting a small sample of marrow, typically from the hip bone, to examine the cells directly under a microscope. A technique called flow cytometry adds another layer of detail. In this test, cells from your blood, marrow, or tissue are tagged with fluorescent markers and passed through a laser, which identifies the exact type and quantity of cells present. Flow cytometry can confirm specific leukemia and lymphoma subtypes, predict how aggressive the disease is, determine whether it will respond to certain treatments, and detect whether cancer has returned after treatment.
Treatment Approaches
Treatment varies widely depending on the type of blood cancer, how aggressive it is, and the patient’s overall health. Chemotherapy remains a backbone of treatment for many hematologic cancers, but several newer approaches have significantly improved outcomes over the past two decades.
Stem Cell Transplants
A stem cell transplant replaces damaged bone marrow with healthy blood-forming stem cells. In an autologous transplant, your own stem cells are collected before treatment and returned afterward. The advantage is that your body won’t reject its own cells, though there’s a small risk that cancer cells may be collected along with the healthy ones. In an allogeneic transplant, stem cells come from a donor. This carries a unique benefit: the donor’s immune cells can recognize and attack remaining cancer cells, an effect called graft-versus-tumor. The tradeoff is a risk of graft-versus-host disease, where the donor’s immune cells attack your healthy tissue.
Recovery from a stem cell transplant takes time. Blood counts may return to normal relatively quickly, but full immune system recovery takes several months after an autologous transplant and one to two years after an allogeneic one.
CAR-T Cell Therapy
One of the most significant advances in blood cancer treatment involves reprogramming a patient’s own immune cells to hunt cancer. In CAR-T cell therapy, T cells are collected from your blood, sent to a laboratory, and genetically engineered to produce special receptors on their surface. These receptors are designed to latch onto specific proteins found on cancer cells. Once the modified T cells are infused back into your body, they seek out and destroy cancer cells while also multiplying to sustain the response.
There are currently several FDA-approved CAR-T therapies for specific blood cancers, including certain types of B-cell leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The treatment is typically reserved for cancers that have relapsed or haven’t responded to other therapies.
Survival Trends Are Improving
Death rates for every major category of hematologic cancer are declining significantly. Leukemia death rates are dropping by about 2% per year, non-Hodgkin lymphoma by 2.4% to 3% per year, and Hodgkin lymphoma by nearly 3% to 4% per year. Myeloma, historically one of the harder blood cancers to treat, has seen the most dramatic improvement, with death rates falling by roughly 5% annually. These trends reflect the cumulative impact of targeted therapies, immunotherapies, and earlier detection improving outcomes across all blood cancer types.